Brokerages expect that Immunomedics (NASDAQ:IMMU) will report ($0.13) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have made estimates for Immunomedics’ earnings. The lowest EPS estimate is ($0.21) and the highest is ($0.04). Immunomedics reported earnings per share of ($0.22) in the same quarter last year, which would suggest a positive year-over-year growth rate of 40.9%. The firm is expected to announce its next earnings report on Wednesday, May 9th.
On average, analysts expect that Immunomedics will report full-year earnings of ($0.96) per share for the current fiscal year, with EPS estimates ranging from ($1.07) to ($0.85). For the next year, analysts forecast that the firm will report earnings of ($0.23) per share, with EPS estimates ranging from ($0.96) to $0.50. Zacks’ earnings per share averages are an average based on a survey of analysts that cover Immunomedics.
Immunomedics (NASDAQ:IMMU) last released its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.09). The firm had revenue of $0.60 million during the quarter, compared to analyst estimates of $0.90 million.
In other news, Director David M. Goldenberg sold 40,000 shares of the firm’s stock in a transaction on Monday, March 5th. The stock was sold at an average price of $17.24, for a total value of $689,600.00. Following the completion of the sale, the director now owns 1,774,285 shares of the company’s stock, valued at $30,588,673.40. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director David M. Goldenberg sold 17,729 shares of the firm’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $17.09, for a total value of $302,988.61. Following the completion of the sale, the director now directly owns 1,774,285 shares of the company’s stock, valued at approximately $30,322,530.65. The disclosure for this sale can be found here. In the last ninety days, insiders sold 77,729 shares of company stock valued at $1,342,589. 14.80% of the stock is currently owned by insiders.
Several institutional investors have recently modified their holdings of IMMU. Calton & Associates Inc. purchased a new stake in shares of Immunomedics during the fourth quarter worth $135,000. Xact Kapitalforvaltning AB purchased a new stake in shares of Immunomedics during the fourth quarter worth $193,000. Sapphire Star Partners LP purchased a new stake in shares of Immunomedics during the fourth quarter worth $323,000. SG Americas Securities LLC raised its holdings in shares of Immunomedics by 27.2% during the third quarter. SG Americas Securities LLC now owns 26,350 shares of the biopharmaceutical company’s stock worth $368,000 after acquiring an additional 5,631 shares in the last quarter. Finally, Virtus Fund Advisers LLC purchased a new stake in shares of Immunomedics during the fourth quarter worth $456,000. 74.51% of the stock is owned by institutional investors and hedge funds.
Shares of IMMU traded down $0.69 during trading hours on Friday, hitting $13.94. 1,608,244 shares of the company were exchanged, compared to its average volume of 1,966,683. The firm has a market cap of $2,425.27, a PE ratio of -17.21 and a beta of 1.62. The company has a quick ratio of 1.26, a current ratio of 1.26 and a debt-to-equity ratio of 1.20. Immunomedics has a one year low of $5.00 and a one year high of $18.93.
ILLEGAL ACTIVITY WARNING: This story was first posted by Ticker Report and is owned by of Ticker Report. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.tickerreport.com/banking-finance/3339151/0-13-eps-expected-for-immunomedics-immu-this-quarter.html.
Immunomedics Company Profile
Immunomedics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company engages in developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.